# A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

> **NCT01685203** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 316 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** ABT-450/r
- **DRUG:** ABT-267
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01685203
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-06
- **Final completion:** 2015-02
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685203, "A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01685203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*